Hodgkin Lymphoma Clinical Trial
Official title:
A Phase I Study of Pentamidine in Combination With Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Verified date | July 2021 |
Source | University of Kentucky |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objective: To evaluate dose limiting toxicity and to determine the recommended phase 2 dose (RP2D) of pentamidine in combination with salvage chemotherapy with ifosfamide, carboplatin and etoposide (ICE) on a 3-weeks schedule in relapsed/refractory classical Hodgkin lymphoma (cHL). Secondary Objective: - To estimate the overall best treatment response at 5- and 16-weeks from study enrollment. Although the clinical benefit of these drugs in combination has not been established, offering this treatment may provide a therapeutic benefit. The patients will be carefully monitored for tumor response and symptom relief, in addition to safety and tolerability. - To estimate the duration of response to the proposed combined therapy. - To measure the protein of regenerating liver-3 (PRL-3) level of expression in patients at time of relapse. - To measure circulating biomarkers of response (soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC)) in serum samples collected throughout treatment and inhibition of (pSTAT, pAKT) in peripheral blood mononucleated cells (PBMC). Exploratory Objective: - To measure cell-free messenger RNA (cfmRNA) in peripheral blood. - To measure cell-free DNA in peripheral blood
Status | Completed |
Enrollment | 1 |
Est. completion date | May 23, 2019 |
Est. primary completion date | May 23, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18 years old or older - Eastern Cooperative Oncology Group (ECOG) performance status =2 - Subjects with histologically confirmed relapse or refractory cHL who had received a front-line anthracycline-containing regimen. - Subjects must have at least one measurable lesion >1.5cm as defined by the lymphoma response criteria. - Subjects must have recovered from their last prior chemotherapy; if they have received an investigational agent, at least 5 half-lives must have expired to assure clearance of prior therapy. - Prior radiation should have been completed at least 4 weeks prior to study Day 1. - Toxicities related to prior therapy must have returned to Grade 1 or less except for alopecia. Peripheral neuropathy must be grade 2 or less. - Adequate bone marrow function defined as: 1) Absolute neutrophil count = 1000/µl and 2) Platelet count = 50,000/µl - Adequate organ function: 1) Creatinine Clearance (CrCl) >60 mL/min and 2) Aspartate Aminotransferase (AST) = 3 upper limit normal (ULN), and Alanine Aminotransferase (ALT) =3 ULN, and Bilirubin = 1.5 ULN (Unless they have Gillbert's disease) - Ability to comply with the treatment, evaluations and required study follow-up. Exclusion Criteria: - Subjects with central nervous system involvement. - Subjects with concomitant second malignancy (except adequately treated non-melanoma skin cancer, ductal carcinoma in-situ, superficial bladder cancer, prostate cancer or in situ cervical cancer) are excluded unless a complete remission was achieved at least 3 years prior to study entry and no additional therapy is required or anticipated. - A serious uncontrolled medical disorder or active infection which impairs the ability of the subject to receive protocol therapy or whose control is jeopardized by the complication of this therapy. - Prior organ allograft or allogeneic bone marrow transplantation. - Positive for HIV (1/2) or known acquired immunodeficiency syndrome. - Positive for hepatitis B Surface Ag, or antibody to hepatitis B core ag, or hepatitis C antibody or hepatitis C RNA in serum. - Ejection fraction less than 45% in subjects with prior anthracycline therapy (measurement of ejection fraction is mandatory). - Corrected QT interval (QTc) prolongation of more than 500. - Women of reproductive age who are unwilling or unable to use an acceptable method to minimize the risk of pregnancy for the entire study period and for at least 18 weeks after the last dose of pentamidine. - Women who are pregnant or breast-feeding. - Women with a positive pregnancy test (serum assay) on enrollment or prior to pentamidine administration. - Sexually active men not using birth control if their partners are women of reproductive age. - Prisoner or subjects who are involuntarily incarcerated. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to pentamidine and/or ifosfamide, carboplatin and etoposide. - No investigational or commercial agents or therapies other than those specified by the protocol may be administered with the intent to treat the patient's malignancy. |
Country | Name | City | State |
---|---|---|---|
United States | University of Kentucky Markey Cancer Center | Lexington | Kentucky |
Lead Sponsor | Collaborator |
---|---|
Reinhold Munker |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Measure cfmRNA Biomarkers | Digital PCR analysis of the peripheral blood plasma will be used to measure cfmRNA during therapy | Up to 112 days | |
Other | Measure Circulating-free DNA (cfDNA) Biomarkers | digital PCR analysis of the peripheral blood plasma will be used to measure cfDNA during therapy. | Up to 112 days | |
Primary | Maximum tolerated dose (MTD) | Dose limiting toxicity (DLT) for hematological and non-hematological toxicities will be graded using National Cancer Institute (NCI) CTCAE Version 5.0 | Up to 21 days | |
Secondary | Determine Efficacy: best overall response | Individual best overall response at 5 and 16 weeks from enrollment, patients will be categorized as either a responder (complete response, partial response) versus nonresponders (stable disease, progressive disease). | Up to 112 days | |
Secondary | Define the Duration of Response | Duration of response as defined starting from the first occurrence of response until disease progression or death. | Up to 112 days | |
Secondary | Identify Immunohistochemistry Biomarkers | Immunohistochemistry staining of paraffin fixed tissue sample and peripheral blood will be done to assess the ability of pentamidine to inhibit its pharmacological target through PRL-3 expression. | Up to 112 days | |
Secondary | Polymerase Chair Reaction (PCR) analysis of Biomarkers | Digital PCR analysis of paraffin fixed tissue sample and peripheral blood will be done to assess PRL-3 expression and compare to the immunohistochemistry staining to determine the ideal testing modality for PRL-3 in cHL. | Up to 112 days | |
Secondary | Identify Phosphorylation Biomarkers | Pentamidine concentration/protein phosphorylation will be measured in PBMC and plasma samples collected throughout treatment. | Up to 112 days | |
Secondary | Identify sCD30 and TARC Biomarkers | Biomarkers: ELISA testing will be used to assess levels of sCD30 and TARC in serum samples collected prior to initiation of therapy and subsequent cycles. | Up to 112 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Active, not recruiting |
NCT03617666 -
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
|
Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Recruiting |
NCT02507479 -
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT02191930 -
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT01943682 -
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
|
Phase 1 | |
Completed |
NCT01393106 -
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
|
Phase 2 | |
Terminated |
NCT00992030 -
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
|
Phase 3 | |
Terminated |
NCT00722865 -
Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma
|
Phase 2 | |
Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Completed |
NCT03242902 -
To Decrease Fatigue With Light Therapy
|
Phase 3 | |
Active, not recruiting |
NCT05205512 -
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial
|
N/A | |
Recruiting |
NCT03681561 -
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03250962 -
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT04510610 -
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
|
Phase 2/Phase 3 | |
Completed |
NCT06295211 -
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
|
||
Active, not recruiting |
NCT02256137 -
A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
|
||
Completed |
NCT02432235 -
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
|
Phase 1 |